{"id":"https://genegraph.clinicalgenome.org/r/74cd6977-6afb-4279-8e2b-1d3239d31ab2v1.0","type":"EvidenceStrengthAssertion","dc:description":"DNAJC12 was first reported in relation to autosomal recessive hyperphenylalaninemia (HPA) in 2017 (Anikster Y, et al., 2017, PMID: 28132689). The co-chaperone DNAJC12 is, together with the 70 kDa heat shock protein (HSP70), thought to be responsible for the proper folding of phenylalanine hydroxylase (PAH), leading to HPA in patients (reviewed in PMID: 29174366).  At least 11 unique variants (e.g. missense, nonsense, frameshift, and large deletion) have been reported in humans. Evidence supporting this gene-disease relationship includes case-level data and experimental data. Biallelic missense variants in this gene have been reported in at least 7 probands in 5 publications (PMIDs: 28132689, 30179615, 28892570, 28794131, 30139987). Variants in this gene segregated with disease in 5 additional family members. More evidence is available in the literature, but the maximum score for genetic evidence has been reached. This gene-disease relationship is supported by the protein interactions that occur between DNAJC12 and PAH, TH, and TPH2 which are consistent with the biochemical abnormalities observed in patients and the functional alteration observed in patient cells with reduced PAH enzymatic activity (PMID: 28132689). In summary, DNAJC12 is definitively associated with autosomal recessive hyperphenylalaninemia.","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/74cd6977-6afb-4279-8e2b-1d3239d31ab2","GCISnapshot":"https://genegraph.clinicalgenome.org/r/500ad0d5-2871-4b25-a96f-0c0816524a4b","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/500ad0d5-2871-4b25-a96f-0c0816524a4b_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10011","date":"2021-01-11T18:49:01.147Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/500ad0d5-2871-4b25-a96f-0c0816524a4b_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10011","date":"2021-01-11T18:48:23.935Z","role":"Approver"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/500ad0d5-2871-4b25-a96f-0c0816524a4b_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/eb439274-23e3-4165-9e66-77bccd074917_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The homozygous nonsense variant Arg72Ter occurs in exon 3 of 5 and is predicted to result in NMD. This variant occurs in the gnomAD South Asian population with a MAF of 0.00003266 (1/30616 alleles).","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d0cf96b8-b60e-4f60-b7ed-234f2fca100c","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28794131","rdfs:label":"2-B","detectionMethod":"Unspecified","phenotypeFreeText":"509 uM Phe","phenotypes":["obo:HP_0008936","obo:HP_0004923"],"previousTesting":true,"previousTestingDescription":"Patient is without PAH mutations or any known defect in BH4 metabolism.","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/eb439274-23e3-4165-9e66-77bccd074917_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28794131","allele":{"id":"https://genegraph.clinicalgenome.org/r/6b7512b6-04dc-4aca-8be4-44e7e323e03f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_021800.3(DNAJC12):c.214C>T (p.Arg72Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/694073"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/56e5d4c6-83ff-41fe-8ddf-09224cb279e8_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The homozygous splice variant c.79-2A>G was confirmed to cause skipping of exon 2 by RT-PCR, resulting in a frameshift and premature stop codon in the following exon, which is predicted to cause NMD (consistent with the significantly reduced transcript levels observed in the patient).","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1c276406-65b2-47e3-861c-de616eb5fd0a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28892570","rdfs:label":"Proband-B","ageType":"AgeAtReport","ageUnit":"Years","ageValue":32,"detectionMethod":"WES with Sanger sequencing confirmation.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"449uM Phe, HVA 37 nM (normal 115-455), 5-HIAA 7 nM (normal 51-204)","phenotypes":["obo:HP_0001300","obo:HP_0004923","obo:HP_0025455","obo:HP_0001256","obo:HP_0003785"],"previousTesting":true,"previousTestingDescription":"No other mutations were detected in genes previously linked/associated with PD. Defects in BH4 metabolism were excluded based on normal levels of urinary pterins and DHPR activity in the driedâ€blood spot.","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/56e5d4c6-83ff-41fe-8ddf-09224cb279e8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28892570","allele":{"id":"https://genegraph.clinicalgenome.org/r/214e3df8-ae02-44d3-bb81-3092786103dc","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_021800.3(DNAJC12):c.79-2A>G","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/694075"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/dd1b2ae2-5bda-4492-9769-9178af4f4416_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The homozygous frameshift variant Gly20Metfs*2 occurs in exon 1 of 5 and is predicted to result in NMD.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/865924dd-6e8d-4099-a156-4ab3ad74f252","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30139987","rdfs:label":"Patient 1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":6,"detectionMethod":"WES with Sanger confirmation in family members.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Phe 271 umol/L","phenotypes":["obo:HP_0004923","obo:HP_0002487","obo:HP_0001332","obo:HP_0001263","obo:HP_0000729"],"previousTesting":true,"previousTestingDescription":"Direct sequencing of PAH was normal. Urinary pterins and DHPR activity were normal.","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/dd1b2ae2-5bda-4492-9769-9178af4f4416_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30139987","allele":{"id":"https://genegraph.clinicalgenome.org/r/d08e1f4d-f21f-4266-a42a-e2b6f0c6dc3d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_021800.3(DNAJC12):c.58_59del (p.Gly20MetfsTer2)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/636261"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/c64c6bc2-70fc-4536-a7bf-4a7e8592a621_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The homozygous missense variant Arg72Pro is predicted to affect DNAJC12 stability (FoldX structural modeling predicts the difference is protein stability to be 13.6 kcal/mol, indicating significant instability). Arg72 is located in the highly conserved J-domain and is essential for maintaining 3D structure, hence the variant is expected to be deleterious. However functional evidence is not provided.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/aa4eda3b-0aad-4b1c-b171-ed15d9b17d98","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28132689","rdfs:label":"C-II-4","ageType":"AgeAtOnset","ageUnit":"Days","ageValue":1,"detectionMethod":"WES with variants in DNAJC12 confirmed by Sanger Sequencing.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"145 uM Phe at NBS, 28 nM 5HIAA, 80 nM HVA, low IQ of 74","phenotypes":["obo:HP_0001263","obo:HP_0004923","obo:HP_0002071","obo:HP_0025455","obo:HP_0003785","obo:HP_0001332","obo:HP_0010553","obo:HP_0000750"],"previousTesting":true,"previousTestingDescription":"No mutations in the genes known to be associated with HPA (PAH, GCH1, PTS, QDPR, and PCBD1) or biogenic amine neurotransmitter defects (SPR, TH, DDC, DAT, and VMAT2) were found in any of the four families using targeted and/or whole-exome sequencing. BH4 metabolism, assessed by measuring urinary pterins and dried blood spot DHPR activity, was normal.","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/c64c6bc2-70fc-4536-a7bf-4a7e8592a621_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28132689","allele":{"id":"https://genegraph.clinicalgenome.org/r/775ec53e-5d48-4d78-aaeb-ef5ffa3338a1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_021800.3(DNAJC12):c.215G>C (p.Arg72Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA16609234"}}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/8b556498-7b83-4585-9d4a-44d3f173e52d_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The c.158-2A>T splice variant affects the canonical acceptor site of intron 2 and likely induces missplicing and a null allele. This is supported by qPCR  analysis of very low DNAJC12 mRNA expression and undetectable protein by Western blot. This variant is present in the gnomAD non-Finnish European population at an MAF of 0.00001776 (2/112,632 alleles).","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/29fd9e93-d7a4-40fd-8451-2f85279e4cff","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28132689","rdfs:label":"B-IV-1","detectionMethod":"Trio WES with variants in DNAJC12 confirmed by Sanger Sequencing.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"460 uM Phe at NBS, 5 nM 5HIAA, 44 nM HVA, 9.5 HVA/HIAA ratio, DQ of 62","phenotypes":["obo:HP_0000338","obo:HP_0001513","obo:HP_0002063","obo:HP_0004923","obo:HP_0007018","obo:HP_0003785","obo:HP_0001300","obo:HP_0001249","obo:HP_0001263","obo:HP_0001063","obo:HP_0031959","obo:HP_0002067"],"previousTesting":true,"previousTestingDescription":"No mutations in the genes known to be associated with HPA (PAH, GCH1, PTS, QDPR, and PCBD1) or biogenic amine neurotransmitter defects (SPR, TH, DDC, DAT, and VMAT2) were found in any of the four families using targeted and/or whole-exome sequencing. BH4 metabolism, assessed by measuring urinary pterins and dried blood spot DHPR activity, was normal.","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/8b556498-7b83-4585-9d4a-44d3f173e52d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28132689","allele":{"id":"https://genegraph.clinicalgenome.org/r/7ed85321-9021-4ccc-96de-b6ab8f2e6535","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_021800.3(DNAJC12):c.158-2A>T","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA5520889"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/500ad0d5-2871-4b25-a96f-0c0816524a4b_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/298a9344-c495-4786-9693-af06985828e8_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28892570","rdfs:label":"Family B","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/298a9344-c495-4786-9693-af06985828e8","type":"Family","rdfs:label":"Family B","member":{"id":"https://genegraph.clinicalgenome.org/r/1c276406-65b2-47e3-861c-de616eb5fd0a"}},"meetsInclusionCriteria":false,"phenotypeNegativeAlleleNegative":0,"phenotypePositiveAllelePositive":2,"phenotypes":"obo:HP_0001300","proband":{"id":"https://genegraph.clinicalgenome.org/r/1c276406-65b2-47e3-861c-de616eb5fd0a"}},{"id":"https://genegraph.clinicalgenome.org/r/12f35049-a30a-46d2-a900-e7cf26448a9d_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28794131","rdfs:label":"Family 2","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/12f35049-a30a-46d2-a900-e7cf26448a9d","type":"Family","rdfs:label":"Family 2","member":{"id":"https://genegraph.clinicalgenome.org/r/d0cf96b8-b60e-4f60-b7ed-234f2fca100c"}},"meetsInclusionCriteria":false,"phenotypeNegativeAlleleNegative":0,"phenotypePositiveAllelePositive":2,"phenotypes":"obo:HP_0004923","proband":{"id":"https://genegraph.clinicalgenome.org/r/d0cf96b8-b60e-4f60-b7ed-234f2fca100c"}},{"id":"https://genegraph.clinicalgenome.org/r/211c49b3-d767-4db6-ab1a-1c5c9e76fae2_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28132689","rdfs:label":"Family A","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/211c49b3-d767-4db6-ab1a-1c5c9e76fae2","type":"Family","rdfs:label":"Family A","member":{"id":"https://genegraph.clinicalgenome.org/r/6b7474a8-6c29-4ad8-aff6-29297928705f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28132689","rdfs:label":"A-IV-2","ageType":"AgeAtOnset","ageUnit":"Days","ageValue":1,"detectionMethod":"Trio WES with variants in DNAJC12 confirmed by PCR amplification of the junction fragment of the exon 4 deletion.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"410 uM Phe at NBS, 28 nM 5HIAA, 192 nM HVA, 6.9 HVA/HIAA ratio","phenotypes":["obo:HP_0000639","obo:HP_0025455","obo:HP_0001562","obo:HP_0003785","obo:HP_0031960","obo:HP_0004923","obo:HP_0008936"],"previousTesting":true,"previousTestingDescription":"No mutations in the genes known to be associated with HPA (PAH, GCH1, PTS, QDPR, and PCBD1) or biogenic amine neurotransmitter defects (SPR, TH, DDC, DAT, and VMAT2) were found in any of the four families using targeted and/or whole-exome sequencing. BH4 metabolism, assessed by measuring urinary pterins and dried blood spot DHPR activity, was normal.","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/d8491bed-236d-4841-9532-27f8494ad6d3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28132689","allele":{"id":"https://genegraph.clinicalgenome.org/r/59e98fe2-68b0-4516-b50c-1937d0ceb941","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_021800.3(DNAJC12):c.298-968_503-2603del","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA16609233"}}}}},"meetsInclusionCriteria":false,"phenotypeNegativeAlleleNegative":0,"phenotypePositiveAllelePositive":2,"phenotypes":"obo:HP_0004923","proband":{"id":"https://genegraph.clinicalgenome.org/r/6b7474a8-6c29-4ad8-aff6-29297928705f"}},{"id":"https://genegraph.clinicalgenome.org/r/12afbc7e-dfa0-46c0-b941-682ebc7e97fb_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28132689","rdfs:label":"Family B","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/12afbc7e-dfa0-46c0-b941-682ebc7e97fb","type":"Family","rdfs:label":"Family B","member":{"id":"https://genegraph.clinicalgenome.org/r/29fd9e93-d7a4-40fd-8451-2f85279e4cff"}},"meetsInclusionCriteria":false,"phenotypeNegativeAlleleNegative":0,"phenotypePositiveAllelePositive":2,"phenotypes":"obo:HP_0004923","proband":{"id":"https://genegraph.clinicalgenome.org/r/29fd9e93-d7a4-40fd-8451-2f85279e4cff"}},{"id":"https://genegraph.clinicalgenome.org/r/7b669b75-c737-4bd6-a2fe-495204830a13_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30139987","rdfs:label":"Afghan Family","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/7b669b75-c737-4bd6-a2fe-495204830a13","type":"Family","rdfs:label":"Afghan Family","member":{"id":"https://genegraph.clinicalgenome.org/r/865924dd-6e8d-4099-a156-4ab3ad74f252"}},"meetsInclusionCriteria":false,"phenotypeNegativeAlleleNegative":0,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0001263","obo:HP_0004923","obo:HP_0000729"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/865924dd-6e8d-4099-a156-4ab3ad74f252"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/f9e52110-de60-41c3-abc5-6984b3717436_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The homozygous frameshift variant Gln88Serfs*6 generates a premature stop codon in exon 3 of 5 and is predicted to result in NMD. This variant is present in the gnomAD East Asian population at a MAF of 0.00005438 (1/18390 alleles).","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e17d82df-be53-47b9-8adb-c1669b00c063","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30179615","rdfs:label":"Feng Patient","ageType":"AgeAtDiagnosis","ageUnit":"Days","ageValue":3,"detectionMethod":"Sanger sequencing of DNAJC12, covering all exons and intron-exon boundaries.","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Phe 185-284 umol/L, elevated Phe/Tyr ratio of 5.3","phenotypes":["obo:HP_0001263","obo:HP_0004923"],"previousTesting":true,"previousTestingDescription":"The results of differential diagnosis showed that the pterin profile(neopterin and biopterin) and DHPR activity were within the normal range. Moreover, neither any pathogenic mutation in PAH and PTS nor abnormal metabolite in the urine organic acids analysis was detected.","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/f9e52110-de60-41c3-abc5-6984b3717436_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30179615","allele":{"id":"https://genegraph.clinicalgenome.org/r/fab23c37-4d86-4301-858b-686487dfb001","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_021800.3(DNAJC12):c.262del (p.Gln88SerfsTer6)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA5520861"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/d8491bed-236d-4841-9532-27f8494ad6d3_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The 6.9 kb deletion removes exon 4 and results in a null allele as confirmed by lack of detectable protein by Western blot.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6b7474a8-6c29-4ad8-aff6-29297928705f"}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/500ad0d5-2871-4b25-a96f-0c0816524a4b_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/500ad0d5-2871-4b25-a96f-0c0816524a4b_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/493e007d-af94-494c-bb4c-28b49e7fb7a1","type":"EvidenceLine","dc:description":"PAH protein level and activity are reduced in cells that express mutant DNAJC12, consistent with the hyperphenylalaninemia phenotype observed in patients. This is thought to be based on the function of the DNAJ proteins in the quality control machinery that transfers its specific protein clients to the molecular chaperone HSC70/HSP70-HSP90 network for proper folding.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f0ab16bc-557b-41ab-ad22-df58a1ca1c88","type":"FunctionalAlteration","dc:description":"Fibroblasts from patient cells, with the Arg72Pro variant, exhibited a lower PAH enzymatic activity than control fibroblasts upon PAH overexpression. Similarly, both PAH endogenous protein levels and levels of overexpressed PAH were reduced in C-II-4 fibroblasts compared to control fibroblasts.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28132689","rdfs:label":"PAH co-chaperone"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/500ad0d5-2871-4b25-a96f-0c0816524a4b_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/25493a65-d005-4a8b-95ee-abe2e8989a7a","type":"EvidenceLine","dc:description":"The interactions of DNAJC12 with PAH, TH, and TPH2 are consistent with the phenotypes of HPA, reduced HVA, and reduced 5-HIAA respectively. Mutations in PAH are a well-known cause of hyperphenylalaninemia and TH is associated with tyrosine hydroxylase deficiency, which has the shared phenotype of dystonia.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/98b0cc43-2536-46e0-9962-ba50637c32bf","type":"Finding","dc:description":"Affinity capture-mass spectrometry data from the human interactome have recently shown that DNAJC12 interacts with several proteins, including tyrosine hydroxylase (TH), peripheral tryptophan hydroxylase 1 (TPH1), and neuronal TPH2 (BioGRID). Overexpression of TPH2 and TH in HEK293 cells confirmed the interactions between these two hydroxylases and DNAJC12. And interaction between DNAJC12 and PAH was also demonstrated by overexpressing PAH in HEK293 cells.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28132689","rdfs:label":"Interaction with PAH, TH, and TPH2","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":2}],"evidenceStrength":"Definitive","sequence":1815,"specifiedBy":"GeneValidityCriteria7","strengthScore":14,"subject":{"id":"https://genegraph.clinicalgenome.org/r/j7yMuy5vugk","type":"GeneValidityProposition","disease":"obo:MONDO_0044304","gene":"hgnc:28908","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_500ad0d5-2871-4b25-a96f-0c0816524a4b-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}